Although the European Medicines Agency (EMA) does not have a mechanism for approving the interchangeability of biosimilars with the originator drugs, this decision on drug switching is left to the EU member states.
Biosimilars, Biologics, FDA Policy and Approvals, Clinical Trials, and Specialty Pharmacy